Deucravacitinib efficacious in scalp psoriasis

The efficacy of deucravacitinib was superior to placebo and apremilast in treating scalp psoriasis, according to pooled results of two studies.
“Scalp psoriasis occurs in [approximately] 80% of patients with psoriasis, has a substantial negative impact on patient mental health and quality of life, and is generally considered difficult to treat,” Andrew Blauvelt, MD, MBA, investigator at Oregon Medical Research Center, and colleagues wrote. “The scalp is typically one of the first areas affected by psoriasis, and scalp psoriasis is accompanied by itch and bothersome scaling.”

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart